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This study examined if 2-week free nicotine replacement therapy (NRT) would be more effective than 1-week free NRT to help
smokers quit smoking at 6 and 12 months. In a single-blinded randomized controlled trial design, 562 Chinese smokers who
attended a smoking cessation clinic in Hong Kong, China, were randomly allocated into two groups (A1 and A2): A1 (𝑛 = 284)
received behavioural counselling with free NRT for 1 week; A2 (𝑛 = 278) received similar counselling with free NRT for 2 weeks.
All subjects received printed self-help materials to support their quitting efforts. A structured questionnaire was used for data
collection, including pattern of NRT use and self-reported 7-day point prevalence quit rate at 6 months and 12 months. Among
the participants, the mean number of cigarettes smoked per day was 18.8 (SD = 10.9). By intention-to-treat analysis, 7-day point
prevalence quit rates were not significantly different between A1 and A2 groups at 6-month (27.5% versus 27.3%; 𝑃 = 0.97) and
12-month (21.1% versus 21.2%; 𝑃 = 0.98) followup.The findings suggest that two-week free NRTwas not more effective than 1-week
free NRT to increase smoking cessation rate among Chinese smokers.
1. Introduction
Smoking and passive smoking are collectively the biggest
preventable cause of death in Hong Kong, with major public
health burden of morbidity, disability, and community costs
[1]. Smoking cessation interventions with behavioral and
pharmacological support are cost-effective [2–4]. However,
there are constraints and variations in the provision of
smoking cessation services in the primary health care setting
[5, 6]. These included lack of trained smoking cessation
counselors, resistance from policy makers to provide the
service, and lack of funding to provide free pharmacotherapy.
The United Kingdom (UK) National Health Service (NHS)
started offering free supply of NRT since early 1998 under the
NHS smoking cessation service [7]. The length of free NRT
supply changed from 1 week in 1998 to full course through
prescription since the publication of National Institute for
Health andClinical Excellence (NICE) guidelines in 2008 [8].
The NICE 2008 guidelines recommended to provide only for
2 weeks supply at the initial consultation, and subsequent
prescriptions should be given only to people who have
demonstrated, on reassessment, that their quit attempt is
continuing [8]. The cost-effectiveness of this program was
reported [9] and suggestions were made to continue the
service on a regular basis [10]. The impact of the provision of
free NRT ranging from one to twelve weeks was also reported
in Canada [11], USA [12], and Australia [13], and it was
argued that similar programs would support the promotion
of smoking cessation service and quit rates.
The first Hong Kong Smoking Cessation Health Center
(SCHC) provided free nicotine replacement therapy (NRT)
for one week to the smokers who came for quitting services
[14]. Clients were advised to buy NRT with their own money
after the use of this initial free supply as there was no
reimbursement mechanism for NRT through the medical
insurance provider. Several previous studies reported that
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reimbursement for full course of 8–12 weeks NRT or other
smoking cessation therapies would increase quit rates [3,
4, 15]. The United Kingdom [16] and United States [17]
clinical practice guidelines recommend the use of NRT for
a full course of 8–12 weeks or longer, but many healthcare
providers cannot afford the full coverage, and many clients
are unlikely to buy NRT after free supplies are finished [18].
In some operational settings, it is apparently not practicable
to comply with the 8–12 weeks recommendation [19, 20].
Several studies reported that the offer of NRT at a reduced
price or no cost increased both the use and cessation rates
[21–23]. Evidence on the cost-effectiveness of increased NRT
use with free supplies and cost sharing would be useful to
support decisions about funding and coverage of smoking
cessation services. Although the provision of a free full course
of NRT would be an incentive to use quitting services, it
might attract less motivated smokers with lower compliance
in usage. This would result in increased expenditure and
NRT wastage without improvement in quit rates. There is a
need to identify effective, low cost interventions that would
be acceptable and affordable in service settings with limited
resources especially in low income countries, but there are
no reports on randomized controlled trials to compare the
effectiveness of providing different quantities of free NRT to
smokers in a smoking cessation clinic.
In Hong Kong, several public and private health sector
providers are offering new smoking cessation services now.
The SCHC was the first regular but part-time service in
HongKong, established in RuttonjeeHospital in August 2000
by a multidisciplinary steering group based on the Hong
Kong Council on Smoking and Health in collaboration with
the Department of Community Medicine, The University of
Hong Kong [14]. Based on the routine operation of the SCHC
with one week free supply of NRT, we reported a higher quit
rate among those who used NRT for 4 weeks or longer (40%)
than those who used NRT for less than 4 weeks (25%) [20].
However, only 16% used NRT for 4 weeks or longer. Because
withdrawal symptoms are higher during the first two weeks
of quitting smoking [24, 25], ensuring the proper use of NRT
during this initial period could help to increase quit rates.
We hypothesized that if, for 2 weeks, supply of NRT could
be given to smokers free of charge, more will continue using
NRT and successfully quit.
We aimed to increase the quit rate by providing one
additional week free NRT. In our earlier analysis of the phase
1 data of our clinic, we found a higher 7-day point prevalence
quit rate among those who used NRT for 2 weeks or longer
(39%) than those who used NRT for one week only (23%)
[20].Therefore, the aim of this studywas to examine if 2-week
free NRT would be more effective than 1-week free NRT to
help smokers quit smoking at 6 and 12 months.
2. Methods
2.1. Study Population. The study took place in Hong Kong
SCHC [14]. Subjects were current smokers who called the
SCHCbooking hotline tomake an appointment and attended
the SCHC during the study period. The smoking cessation
counselor recruited eligible smokers for the trial. To be
eligible for the trial, the subjects had to be (a) aged 16 or above,
(b) able to speak Chinese, (c) smoking at least 5 cigarettes
daily, (d) clearly motivated to quit, (e) willing to use NRT, (f)
free from any serious health problems that may make them
unsuitable for using NRT (e.g., recent stroke, palpitations,
or other life threatening conditions), (g) not receiving other
forms of smoking cessation programs, and (h) signatory to
an informed consent form. Subjects were excluded if they
did not meet the inclusion criteria or if they were on regular
psychotropic medications.
2.2. Study Design. This was a single-blinded randomized
controlled trial (RCT) conducted in the Hong Kong SCHC.
The study protocol was approved by the Ethics Committee of
the Faculty of Medicine, the University of Hong Kong.
2.3. Procedures. Eligible selected subjects signed the consent
form and completed the baseline measures (filling in a
questionnaire and measurements of body weight, height,
blood pressure, and exhaled carbon monoxide) before the
counselor opened a serially numbered, opaque, and sealed
envelope (SNOSE) to reveal the random assignment of each
smoker to A1 or A2 group. The random numbers for group
assignment were generated by the research assistant (not the
counselors) of the project using a personal computer before
subject recruitment. Subjects in both groups received 20min
face-to-face individual smoking cessation counseling by the
trained smoking cessation counselor and were provided with
a 1-week or 2-week free supply of NRT (either gum or
patches, according to subject’s preference). Participants in
the A1 group received 1-week free NRT, and the A2 group
received 2-week free NRT supplies. The NRT was prescribed
using the guideline based on the subject’s daily cigarette
consumption [17]. All participants received NRT after the
initial counseling session. At initial contact, participants in
both groups received a self-help quitting pamphlet, “Easy
Steps to Quitting,” developed by the Hong Kong Council on
Smoking and Health.
At 1 week, a telephone call was made to each participant
to check whether they were facing any difficulties, and a
brief counseling (less than 5 minutes) was given if requested.
Subjects in both groups were contacted, face-to-face for all
those who attended the SCHC and by telephone for all those
who did not attend, at 1 and 3 months for a follow-up
assessment and relapse prevention counseling. The standard
questionnaire was used at each follow-up visit or other
contacts. Each session lasted for an average of 15 minutes. To
assess the final outcome, all subjects were again followed up at
6 and 12months by telephone for an average of 10minutes. An
independent interviewer, who was unaware of the subject’s
group allocation, carried out the 6 and 12 months follow-
up interview. At 6 months, those who had stopped smoking
(not smoking for 7 days or more preceding the follow-up
interview) were invited to attend the SCHC for biochemical
validation by measuring carbon monoxide level in expired
air. We offered an incentive of HK$200 (US$1 = HK$7.8) for
attending the validation test.
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2.4. Intervention. The 20min face-to-face smoking cessation
counseling intervention included two components of the
information on the health consequences of smoking and
the smoking cessation counseling. Counselling was provided
based on the queries and the needs of individual clients
which were determined by their smoking status, physi-
cal dependence and the perceived barriers to quitting. A
nondirective patient-centred intervention utilizing motiva-
tional interviewing techniques and the 5R (relevance, risk,
rewards, roadblocks, and repetition) approach was used to
boost motivation [26]. The smoking cessation counselor
encouraged all smokers to set a quit date and provided tips
to smokers for successful quitting and instructions to use
NRT as appropriate. Details of the counseling method have
been described in another report [14]. A hotline number
was available to all study participants through which they
could contact counselors to discuss any difficulties in their
quitting process and to receive problem-oriented solutions.
However, only a very small number called the hotline for
advice. Participants in both groups were advised to buy
NRT using their own money after finishing the free supply.
The recommended duration of NRT use was 8–12 weeks
depending on the NRT type (patch or gum) given [25].
All counselors were trained smoking cessation coun-
selors, attended a 4-day training course on smoking cessation
skills organized by the University of Hong Kong, and passed
the final assessment examination. To ensure the quality of the
intervention, regular meetings with the counselors were held
every 2 months for case sharing and evaluation.
2.5. OutcomeMeasures. Themain outcomewas self-reported
7-day point prevalence quit rate at 6 months (defined as not
smoking during the 7 days preceding the 6-month followup).
We used this as our primary outcome measure because this
measure is most commonly used across smoking cessation
studies. We have also reported the same measures in our ear-
lier studies among theHongKongChinese people [14, 20, 27].
To report the complete picture of the intervention, we
have also measured several secondary outcome variables [14,
20, 27]: biochemically validated (expired carbon monoxide
reading <9 ppm [28]) 7-day point prevalence quit rate at
6 months, 24-hour point prevalence quit rate at 6 and 12
months without validation (defined as not smoking during
the 24-hours preceding the 6-month and 12-month fol-
lowups), continuous quit rate at 6 and 12 months without
validation (defined as continuously not smoking during the 6
months and 12 months preceding the 6-month and 12-month
followups), and reduction rate (had not quit but had reduced
smoking by at least 50% from the baseline level at 6 and 12
months) among those who were not able to quit and whether
subjects had quitted for at least 24 hours at some point before
6-month and 12-month followup.
2.6. Sample Size and Power. Our sample size calculation was
based on our earlier studies among the same clinic population
[14, 20]. In the earlier report, we reported a higher quit
rate among those who used NRT for 2 weeks (39%) versus
those who used NRT for 1 week (23%) [20]. In another
evaluation report, we have reported a quit rate of 27% (95%
confidence interval, 25–30%) among the attendees of the
SCHC [14]. Based on these previous results, for the current
study, we intentionally adopted a conservative estimate and
hypothesized that, by giving 2 weeks’ free NRT supply, the
quit rate would be 24% in the 1-week NRT group and would
increase to at least 36% in the 2-week NRT group, with an
absolute effect size of 12%. This yielded a total sample size of
248 in each group, based on a significance level of 5% and
power of 90%. Assuming a 10% drop-out rate, we estimated
a total sample size of 544 (272 in each group). We achieved a
final sample size which was a bit higher than planned so as to
obtain a greater power.
All the 716 subjects who attended the clinic underwent
screening for inclusion, and 118 were excluded. Of the 598
eligible subjects, 36 refused to participate, and 562 were
available for randomization (Figure 1).
2.7. Data Collection and Analysis of Data. A standardized
structured questionnaire was used, the details of which
have been described elsewhere [14, 20]. The questionnaire
included demographic information (gender, marital status,
age, occupational status, educational attainment, and house-
hold income) and tobacco use related information (smoking
and quitting history, spouse or other household members’
smoking status, nicotine dependency level, and stages of
change). Carbon monoxide, using Bedfont piCO+ Smoker-
lyzer, in expired air wasmeasured among those who attended
the SCHC for biochemical validation at 6 months. At 6-
month and 12-month follow-up contacts, participants were
asked about the helpfulness of the smoking cessation coun-
seling, the follow-up contacts, and the self-help materials.
We analyzed the data with SPSS for Windows, version
10.0. The baseline characteristics of two groups (A1 and
A2) were compared by Chi-square test. To test the efficacy
of the two different lengths of NRT use, the two groups
were compared. Rates of tobacco abstinence and reduction
between groups were compared using Pearson’s Chi-square
test, together with odds ratios (OR) and their 95% confidence
intervals (CI). We conducted all analyses on an intention-to-
treat basis. Follow-up variables with missing data were set to
their baseline values (e.g., current smoker). A two-tailed 𝑃
value of less than 0.05 was considered statistically significant.
3. Results
3.1. Baseline Characteristics. Of the 562 subjects, most were
males (73.3%), married or cohabiting (52.8%), had attained
education to secondary school level or above (90.4%), and
were currently employed (75.6%). The mean number of
cigarettes smoked per day was 18.8 (SD = 10.9), and the
average number of years of smoking was 18.5 (SD = 10.9).
No significant differences were found between groups. Table 1
shows that the A1 and A2 groups were similar in their
demographic and other variables.
3.2. Pattern of NRTUse. Overall, less than half of the subjects
used NRT for at least 2 weeks, and only about a quarter
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Eligible subjects 
Assessed for eligibility
(n = 716)
(n = 598)
Excluded (n = 118):
(2) did not have intention to
quit = 18
(3) got diseases that
cigarettes per day = 29
(6) not willing to use NRT = 9
Refused participation = 36
Agreed to
participate in the
trial and randomized
(n = 562)
Allocated to group 2, A2
Two-week NRT
(n = 278)
Allocated to group 1, A1
One-week NRT
(n = 284)
One-month followup (246 completed):
no response n = 16)
One-month followup (253 completed):
no response n = 17)
Three-month followup (219 completed):
6
no response n = 42)
Three-month followup (231 completed):
no response n = 36)
Six-month followup (203 completed):
no response n = 45)
Six-month followup (201 completed):
no response n = 52)
Eligible for biochemical validation at 6
Validation done (n = 39)
(refused n = 29, did not show up n = 8)
Eligible for biochemical validation at 6
Validation done (n = 28)
(refused n = 38, did not show up n = 12)
12-month followup (182 completed):
no response n = 45)
Note: no validation was done at 12 months
12-month followup (182 completed):
no response n = 47)
Note: no validation was done at 12 months
(4) mental illness = 23
(1) age< 16 = 23
was not suitable to use NRT = 16
(5) smoked less than 5
lost to followup (n = 31) lost to followup (n = 32)
lost to followup (n = 59)lost to followup (n = 53)
lost to followup (n = 75)
lost to followup (n = 96)
lost to followup (n = 83)
(refused n = 9, untraceable n = 21, and(refused n = 8, untraceable n = 23, and
(refused n = 4, untraceable n = 13, and
(refused n = 6, untraceable n = 10, and(refused n = 3, untraceable n = 11, and
(refused n = , untraceable n = 11, and
months (n = 78) months (n = 76)
(refused n = 17, untraceable n = 34, and(refused n = 18, untraceable n = 37, and
lost to followup (n = 102)
Figure 1: Flow of participants through trial.
used it for at least 4 weeks. All of those who could not be
contacted were considered as non-users (Table 2). There was
no significant difference in the patterns of NRT use between
subjects in the A1 and A2 groups except a higher proportion
of those in the A2 group who used NRT for at least 2 weeks
(53.6% versus 41.5%) (𝜒2 = 0.54, df = 1, 𝑃 = 0.004).
3.3. Quitting Outcome. Table 3 shows that, at 6-month
followup, the self-reported 7-day point prevalence quit rate
was similar in the A1 group (27.5%; 78/284) and the A2 group
(27.3%; 76/278) (OR = 1.0, 95% CI: 0.7–1.4, 𝑃 = 0.97). The
self-reported quit rate at 12 months was also almost similar in
groups A1 (21.1%; 60/284) and A2 (21.2%; 59/278) (OR = 1.0,
95% CI: 0.7–1.5; 𝑃 = 0.98). The biochemically validated quit
rate at 6 months was higher in group A2 (12.6%; 35/278)
than in group A1 (7.7%; 22/284), but the difference was not
statistically significant (OR = 1.7, 95% CI: 0.9–3.0). We also
found no significant differences in other secondary outcome
measures between the two groups at 6 months and 12 months
(Table 3).
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Table 1: Baseline demographic, smoking, and other characteristics of the two groups of participants.
Characteristics
A1
(𝑛 = 284)
% (𝑛)
A2
(𝑛 = 278)
% (𝑛)
𝑃 value for 𝜒2 test
Demographics:
Gender 0.84
Male 77.8 (221) 78.8 (219)
Female 22.2 (63) 21.2 (59)
Marital status 0.57
Single 39.4 (112) 42.1 (117)
Married/cohabiting 53.2 (151) 52.5 (146)
Divorced/separated/widowed 7.4 (21) 5.4 (15)
Occupational status 0.20
Currently employed 74.3 (211) 77.0 (214)
Unemployed 9.9 (28) 12.9 (36)
Housewife 8.1 (23) 4.0 (11)
Full-time student 3.5 (10) 3.2 (9)
Retired 4.2 (12) 2.9 (8)
Age, years 0.77
25 or below 16.2 (46) 17.3 (48)
26–35 39.8 (113) 35.6 (99)
36–45 24.6 (70) 25.5 (71)
46 or above 19.4 (55) 21.6 (60)
Educational attainment 0.56
Primary as below 9.9 (28) 9.4 (26)
Secondary (F1–F5) 61.3 (174) 57.6 (160)
Matriculation or above 28.9 (82) 33.1 (92)
Monthly household income 0.93
HK$9,999 or less 22.5 (64) 21.6 (60)
HK$10,000–29,999 56.3 (160) 56.1 (156)
HK$30,000 or above 21.1 (60) 22.3 (62)
Tobacco use related:
Daily cigarette consumption in the past month 0.30
10 or less 27.8 (79) 25.5 (71)
11–20 46.5 (132) 52.9 (147)
21 or above 25.7 (73) 21.6 (60)
Nicotine dependency level† 0.58
Low 26.1 (74) 28.4 (79)
Moderate 32.7 (93) 28.8 (80)
Severe 41.2 (117) 42.8 (119)
Years of smoking 0.83
1–10 28.2 (80) 26.3 (73)
11–20 36.6 (104) 36.3 (101)
20 or more 35.2 (100) 37.4 (104)
Spouse or household members’ smoking status 0.82
Smoker 12.3 (35) 12.9 (36)
Nonsmoker 87.7 (249) 87.1 (242)
No. of previous quitting attempt (s) 0.55
None 28.5 (81) 26.3 (73)
One or more 71.5 (203) 73.7 (205)
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Table 1: Continued.
Characteristics
A1
(𝑛 = 284)
% (𝑛)
A2
(𝑛 = 278)
% (𝑛)
𝑃 value for 𝜒2 test
Length of abstinence in the last quitting attempt∗ 0.08
1–30 days 71.4 (145) 79.0 (162)
>30 days 28.6 (58) 21.0 (43)
Stage of change 0.18
Precontemplation 6.3 (18) 5.8 (16)
Contemplation 71.8 (204) 64.7 (180)
Preparation 18.0 (51) 25.5 (71)
Action 3.9 (11) 4.0 (11)
Choice of NRT use 0.65
Patch 71.2 (202) 69.0 (192)
Gum 28.8 (82) 31.0 (86)
Note: US$1 = HK$7.8.
†Nicotine dependence level was measured by Fagerstrom scale. It is divided into 3 levels: low (score 0–3), moderate (score 4-5), and severe (score = 6–10).
∗This question is only for those subjects who had attempted quitting smoking in the past.
Table 2: NRT use among subjects in the two groups.
Duration of NRT use A1 (𝑛 = 284) A2 (𝑛 = 278)
2 weeks or more 41.5∗ 53.6∗
4 weeks or more 22.9 24.8
8 weeks or more 7.4 6.8
Note: all of those who were not available at followup were considered as
nonusers.
∗Significant difference between the two study groups (Chi-square = 0.54,
df = 1, 𝑃 = 0.004).
3.4. Other Exploratory Outcomes. In relation to the satis-
faction with the intervention, participants overwhelmingly
found the cessation counseling helpful (94.8%), the follow-up
contacts useful (91.2%), and the self-help quitting materials
useful (89.3%). We have explored the quit rate based on the
type of NRT use and found that patch users and gum users
did not differ in the quitting outcome at both 6months and 12
months (𝑃 > 0.05) (data not shown). In relation to the call to
the counselor’s hotline, only eight participants (group A1 = 5
and group A2 = 3) called the hotline, and all the calls were
for more NRT supply and general enquiry. Due to the small
number, we did not explore the quitting outcome based on
the calling status to the hotline.
4. Discussion
Our findings showed that giving 2 weeks’ free NRT over
1 week’s free NRT did not increase quit rate at 6 months
and 12 months among Chinese smokers attending a smoking
cessation clinic in Hong Kong. Although a higher proportion
in the A2 group used NRT for at least 2 weeks probably
due to the free supply, there was no impact on the reported
overall quit rates. One possible explanation was that giving 1-
week or 2-week free NRT did not change smokers’ adherence
to NRT use (defined as NRT use for 4 weeks or longer
[20]), as the prevalence of NRT use was almost identical
in both groups, (22.9% in A1 group versus 24.8% in A2
group). Another explanation was that 1-week free NRT was
enough to encourage motivated smokers to continue to use
it for a longer duration, because some smokers who attended
the clinic were already motivated to quit and giving 1-week
or 2-week supply did not have any measurable effect on
their determination to quit and buy NRT afterwards. This
further reflects the importance of self-motivation in quitting
smoking [29]. Also, the price ofNRT as compared to the price
of the cigarettes is an important consideration for smokers. In
Hong Kong, during the study period, the price of one-week
NRT (US$38) was similar to the price of 8 packs of cigarettes.
Therefore, buying NRT rather than cigarettes did not provide
any immediate financial incentives to the participants.
Whether the suggestion that full free coverage for smok-
ing cessation service including both behavioral counseling
andNRT [3, 4] would bemore beneficial for Chinese smokers
than partial coverage for NRT needs to be further tested.
Although the United States Clinical Practice Guideline Treat-
ing Tobacco Use and Dependence recommends that health
service organizations cover the cost for NRT [25], our results
suggest that increased coverage to two weeks may not be
more effective than a minimal period of one week. Because
of the high cost of NRT, initial support for free NRT only
for 1 week would be appropriate for services which are not
well funded.Motivated smokers should be encouraged to buy
and use NRT after trying the free NRT for 1 week. Providing
nonmotivated or nonadherent smokersmore freeNRTwould
result in wastage and would not increase NRT usage rate or
quit rate. One study found that the percentage of the amount
used was the inverse of the amount provided [30]. That is, if
a caller was given a 1- or 2-week supply of medication, they
would more likely use a larger percentage of it than those
given a 6-week supply [30]. Several previous reports and
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Table 3: Quitting status using different outcome measures in the two groups at 6-month and 12-month followups, by intention to treat∗.
Outcome measures
6 months 12 months
A1
(𝑁 = 284)
𝑁 (%)
A2
(𝑁 = 278)
𝑁 (%)
𝑃 values OR (95% CI)
A1
(𝑁 = 284)
𝑁 (%)
A2
(𝑁 = 278)
𝑁 (%)
𝑃 values OR (95% CI)
Main outcome
Self-reported 7-day point
prevalence quit rate 78 (27.5) 76 (27.3) 0.97 1.0 (0.7–1.4) 60 (21.1) 59 (21.2) 0.98 1.0 (0.7–1.5)
Secondary outcomes
Biochemically validated (CO
level in exhaled air) 7-day point
prevalence quit rate
22 (7.7) 35 (12.6) 0.06 1.7 (0.9–3.0) NA NA NA NA
Self-reported 24-hour point
prevalence quit rate 78 (27.5) 76 (27.3) 0.97 1.0 (0.7–1.4) 60 (21.2) 59 (21.2) 0.98 1.0 (0.7–1.5)
Self-reported continuous
abstinence 71 (25.0) 69 (24.8) 0.96 1.0 (0.7–1.5) 52 (18.3) 51 (18.3) 0.99 1.0 (0.7–1.5)
Had not quit but had reduced
smoking by at least 50% from the
baseline level
49 (17.3) 50 (18.0) 0.48 1.1 (0.7–1.9) 39 (13.7) 44 (15.8) 0.48 1.2 (0.7–1.9)
Stopped smoking for at least 24
hours at some point prior to the
interview
123 (47.9) 127 (53.1) 0.24 1.2 (0.9–1.8) 110 (38.7) 112 (40.3) 0.71 1.1 (0.8–1.5)
Note: OR: odds ratio; CI: confidence interval; NA: not applicable.
∗Subjects who did not complete the intervention (withdrawn/could not be contacted) were considered not quitting. Those who had no validation were also
considered as not quitting.
data on wastage are often not reported by service providers
offering full NRT coverage [12, 31], and further revaluation
on wastage and cost-effectiveness is needed.
The study had several limitations. Because followup lasted
for only 12 months, results on longer term quit rate were
not available. Quitting was not verified biochemically at 12
months, because we measured main outcomes at 6 months
and two-third did not return for validation. However, valida-
tion is not required in low-intensity population-based inter-
ventions such as the present study [32]. Another limitation
was that some participants were lost to followup despite our
active efforts which might have weakened the effectiveness of
the intervention. Also, our sample size calculation was based
on the anticipated dropouts at 6 months only. This is because
we did not plan to conduct 12-month followup at the initial
stage, but finally we were able to conduct a followup at 12
months. We thought reporting both 6 and 12 months results
will provide a complete picture of the study. Finally, intent-
to-treat analysis tends to be conservative and underestimate
the effect size.
Our study should have important practical implications.
As the first study showing effectiveness of one-week freeNRT,
our findings can help policy makers to budget for NRT costs
in smoking cessation services and for insurance companies
to consider reimbursement to cover NRT expenditure for
insured smokers. Our study also provides evidence from an
East Asian population that a behavioral counseling program
together with minimal free provision of NRT can produce a
satisfactory quit rate, which is comparable to or higher than
other programs providing full coverage for NRT [2, 6].
The optimal duration to provide tobacco cessation medi-
cation is still undefined. The USPHS Guideline varies from
no more than 8 weeks for nicotine patch to up to 12
weeks for nicotine gum, nicotine lozenge, bupropion SR,
and varenicline [33]. The Centers for Disease Control and
Prevention (CDC) recommends quitlines that provide a
minimum of two weeks for all callers and up to 8 weeks
for those financially disadvantaged [34]. Bauer et al. [35]
argued that the individual’s experiencewith tobacco cessation
medication may increase the awareness of the benefits of
these medications and the utilization of smoking cessation
service for future quit attempts—especially for those who
may have never used either intervention before. In another
study, as little as one week of free NRT increased calls to
a quitline and increased tobacco abstinence rates compared
to not providing NRT [30]. However, many smokers can
quit successfully only with behavioral counseling [36]; over-
emphasis on NRT or other medications should be avoided.
Although linking free tobacco cessation medications for all
cessation support seekers with counseling ensures that more
tobacco users will receive both types of interventions [37]
to achieve a greater likelihood of abstinence [17]; in many
developing countries, this may not be feasible [5]. Service
providers in many developing countries often cannot afford
any free NRT or other smoking cessation medications and
would rely on advice or counseling only. Therefore, specific
smoking cessation program should be customized based on
the resources available and the feasibility of the intervention
within the given healthcare setting. However, there would be
8 BioMed Research International
a need for rigorous evaluation of any pilot programs before
their wider implementation to the population level.
In conclusion, this study demonstrates no additional
advantage of offering free NRT for 2 weeks as compared
with 1 week to Chinese smokers in relation to self-reported
or biochemically validated quitting smoking. Provision for
counseling and/or free NRT or other cessation medications
should be based on the availability of resources of a specific
program. However, limited course of medication for brief
periods of time (i.e., for 1 week) as a promotional tool
encourages smokers to seek cessation support and may
increase quit rate [30].
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